Overview

Study Assessing Metabolism, Excretion and Pharmacokinetics of a Poly (ADP-Ribose) Polymerase (PARP) Inhibitor in Patients With Solid Metastatic Tumours

Status:
Completed

Trial end date:
2008-10-01

Target enrollment:

Participant gender:

Summary

Open, non-randomized, radiolabelled, single centre study designed to characterize the metabolism, excretion and pharmacokinetics of a single oral dose of 100 mg [14C]-radiolabelled AZD2281 (KU-0059436) in patients with advanced or metastatic solid tumours.

Phase:

Phase 1

Details

Lead Sponsor:

AstraZeneca

Collaborator:

KuDOS Pharmaceuticals Limited

Treatments:

Olaparib